- +852 4750 3485
- info@mycancerinfo.org
Metastatic melanoma represents one of the most aggressive forms of skin cancer, particularly when it spreads beyond the primary site. Although advances in immunotherapy and targeted therapies have improved outcomes, many patients still experience limited response or disease progression.
Recent research has explored a novel radioactive drug using targeted alpha therapy (TAT), offering a potential new strategy to selectively destroy melanoma cells while minimising damage to surrounding healthy tissues.
Metastatic melanoma is associated with:
Radiotherapy has traditionally been used, but conventional approaches—particularly those using beta-emitting radiation—may affect both tumour and healthy tissues due to longer radiation range and lower energy precision.
Targeted alpha therapy is an advanced form of radiotherapy that uses alpha particle–emitting isotopes attached to molecules designed to target cancer cells.
This combination allows for highly localised tumour destruction with potentially reduced impact on nearby healthy tissue.
Researchers in Japan developed a new radiopharmaceutical based on:
The compound, referred to as an ¹¹¹At-labelled α-MSH peptide analogue, is designed to selectively bind to melanoma cells and deliver targeted radiation.
Metastatic melanoma represents one of the most aggressive forms of skin cancer, particularly when it spreads beyond the primary site. Although advances in immunotherapy and targeted therapies have improved outcomes, many patients still experience limited response or disease progression.
Recent research has explored a novel radioactive drug using targeted alpha therapy (TAT), offering a potential new strategy to selectively destroy melanoma cells while minimising damage to surrounding healthy tissues.
The drug demonstrated strong accumulation in tumour tissue, with reduced uptake in normal organs, suggesting improved targeting specificity.
In melanoma-bearing animal models, the therapy showed dose-dependent tumour inhibition, indicating increasing effectiveness with higher dosing levels.
The compound was cleared relatively quickly from non-target organs, which may help reduce systemic toxicity.
The drug remained stable in circulation, reducing the risk of radioactive leakage and unintended exposure.
This research reflects a broader shift toward precision radiopharmaceuticals in oncology.
Potential advantages include:
Targeted radiotherapy is increasingly seen as a complement to existing approaches such as immunotherapy and targeted drugs.
While promising, this therapy is not yet available as a standard treatment.
The development of an astatine-211–based targeted alpha therapy represents a promising advancement in the treatment of metastatic melanoma.
By combining molecular targeting with high-energy, short-range radiation, this approach may offer a more precise and effective way to treat aggressive cancers in the future.
Further clinical research will be essential to determine its role in patient care.
Learn how precision medicine can help with your cancer treatment
The effectiveness of cancer treatment varies among each patient.
